Strolll Secures £10.4m to Boost Neurorehabilitation Innovations

Strolll, a digital therapeutic software company based in Staffordshire, has successfully raised £10.4 million in a Series A funding round. This significant injection of capital, led by IW Capital, will be directed towards ramping up sales and marketing activities and furthering product development in neurorehabilitation therapies. Strolll's platform, which employs augmented reality (AR) glasses, is designed to assist individuals with neurological disorders such as Parkinson's disease, stroke, and Multiple Sclerosis by providing enhanced, clinically-proven rehabilitation therapy. The funding will also enable Strolll to broaden its regulatory approvals, allowing for a wider application of its therapies. Earlier, Strolll expanded into the US market through a $3 million collaboration with Cleveland Clinic, which transferred IP in an exclusive software licensing deal and took a shareholder position in the company. This growth positions Strolll as a leader in the digital health sector targeting neurological disorders. Both Strolll and its investors emphasize the transformative impact the company's technologies have in improving patient care.